Corbus Pharmaceuticals Holdings, Inc. cotiza a 5.27 USD y tiene una capitalización bursátil de $102M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a pe…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.81 | $-1.23 | $-1.25 |
| Estimado | $-1.21 | $-1.24 | $-1.22 | $-1.58 |
| Sorpresa | — | -46.0% | -0.8% | +20.9% |
| Métrica | CRBP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -53.2% | -40.4% | -12.8% |
| ROA | -46.7% | -32.0% | -14.7% |
| Current Ratio | 8.07 | 2.84 | +5.23 |
| Debt / Equity | — | 0.28 | — |